Social determinants of health, including education and income level and race/ethnicity, are drivers of declining cardiometabolic health in the US, says investigator Meghan O'Hearn.
Part 1: US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
Part 2: Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
Meghan O’Hearn, MS, is a doctoral student at the Friedman School of Nutrition Science and Policy at Tufts University under the mentorship of Dariush Mozaffarian, MD. O'Hearn's research focus incudes understanding the use of dietary quality metrics to monitor global diet-related disease burdens as well as how research can collaborate with the food industry to address the growing double burden of malnutrition globally.
Reference: O'Hearn M, Lauren BN, Wong JB, Kim DD, Mozzafarian D. Trends and disparities in cardiometabolic health among US adults, 1999-2018. J Am Coll Cardiol. 2022. Published online ahead of print July 4, 2022. https://www.jacc.org/doi/10.1016/j.jacc.2022.04.046
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
August 26th 2025Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial
August 26th 2025Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
2 Commerce Drive
Cranbury, NJ 08512